Meeting
2021 ASCO Annual Meeting
Phase II study of ceralasertib (AZD6738), in combination with durvalumab in patients with metastatic melanoma who have failed prior anti-PD-1 therapy.
Authors
Minsuk Kwon
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Minsuk Kwon , Seung Tae Kim , Simon Smith , Claire Smith , Peter G. Mortimer , Bienvenu LoembE , Iwanka Kozarewa , Emma Dean , Jeeyun Lee
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03780608
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9514)
DOI
10.1200/JCO.2021.39.15_suppl.9514
Abstract #
9514
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer.
First Author: Minsuk Kwon
Poster
2018 ASCO Annual Meeting
A phase 2, multicenter study to assess the efficacy and safety of autologous tumor-infiltrating lymphocytes (LN-144) for the treatment of patients with metastatic melanoma.
First Author: Amod Sarnaik
Poster
2018 Gastrointestinal Cancers Symposium
A randomized phase 2 study of durvalumab monotherapy and in combination with tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS study.
First Author: Eileen Mary O'Reilly
Poster
2017 ASCO Annual Meeting
Final results of a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab combination treatment in patients with stage IIIB-IV unresectable or metastatic melanoma.
First Author: Robert Hans Ingemar Andtbacka